Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Icecure Medical ( (ICCM) ) has issued an update.
IceCure Medical has received an Intention to Grant Notice from the European Patent Office for its innovative cryogenic system connector technology used in its XSense™ system, marking a significant milestone in their intellectual property portfolio. This development is expected to enhance IceCure’s leadership in the cryoablation market, potentially accelerating the global adoption of its minimally invasive tumor treatment solutions and addressing unmet needs in the tumor ablation market, which was valued at $1.67 billion in 2023.
More about Icecure Medical
IceCure Medical is a company that develops and markets advanced cryoablation therapy systems utilizing liquid nitrogen for the treatment of tumors, both benign and cancerous. The company’s primary focus areas include breast, kidney, bone, and lung cancer. Their minimally invasive technology offers a safe and effective alternative to traditional surgical tumor removal, marketed globally through their flagship ProSense® system, with regulatory clearance in major regions including the U.S., Europe, and China.
YTD Price Performance: 0.0%
Average Trading Volume: 735,934
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $67.38M
See more insights into ICCM stock on TipRanks’ Stock Analysis page.
